Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an announcement.
Neuren Pharmaceuticals has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for ordinary fully paid shares under code NEU. The latest daily buy-back report, dated 20 April 2026, shows that the company repurchased 16,000 shares on the previous trading day, bringing the cumulative total bought back to 156,700 shares, signaling continued capital management activity and potential support for the share price.
The update follows an initial buy-back notification lodged in February 2026 and a prior update on 17 April 2026, reflecting Neuren’s regular disclosure of buy-back progress to the market. By steadily retiring equity through on-market purchases, the company may be aiming to optimize its capital structure and enhance shareholder value, a move that is closely watched by investors assessing management’s confidence and capital allocation priorities.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$19.10 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a publicly listed biotechnology company trading on the ASX under the code NEU. It has ordinary fully paid shares on issue and operates within the pharmaceuticals sector, focusing on drug development and related healthcare innovations for investors in the Australian market.
YTD Price Performance: -32.89%
Average Trading Volume: 546,037
Technical Sentiment Signal: Sell
Current Market Cap: A$1.58B
Learn more about NEU stock on TipRanks’ Stock Analysis page.